Price
$23.745
Decreased by -9.92%
Dollar Volume (20D)
43.28 M
ADR%
3.89
Earnings Report Date (estimate)
May 6, 24
Shares Float
109.76 M
Shares Outstanding
164.18 M
Shares Short
9.42 M
Market Cap.
3.9 B
Beta
0.44
Price / Earnings
N/A
20D Range
23.36 26.83
50D Range
23.36 32.59
200D Range
20.3 33.99
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Feb 27, 24 0.28
Increased by +207.69%
0.3
Decreased by -6.67%
Nov 2, 23 -0.4
Decreased by -135.29%
-0.43
Increased by +6.98%
Aug 2, 23 0.01
Increased by +104.76%
-0.08
Increased by +112.5%
May 8, 23 -0.27
Increased by +18.18%
-0.21
Decreased by -28.57%
Feb 27, 23 -0.26
Increased by +3.7%
-0.24
Decreased by -8.33%
Nov 2, 22 -0.17
Decreased by -88.89%
-0.19
Increased by +10.53%
Aug 8, 22 -0.21
Increased by +22.22%
-0.25
Increased by +16%
May 4, 22 -0.33
Increased by +21.43%
-0.6
Increased by +45%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 211.7 M
Increased by +61.96%
-65.18 M
Decreased by -139.77%
Decreased by -30.79%
Decreased by -48.04%
Jun 30, 23 165.24 M
Increased by +22.79%
1.11 M
Increased by +103.28%
Increased by +0.67%
Increased by +102.67%
Mar 31, 23 118.46 M
Increased by +2.59%
-43.02 M
Increased by +61.95%
Decreased by -36.32%
Increased by +62.91%
Dec 31, 22 136.49 M
Increased by +4.38%
-41.73 M
Increased by +3.18%
Decreased by -30.57%
Increased by +7.24%
Sep 30, 22 130.71 M
Decreased by -0.68%
-27.18 M
Decreased by -88.03%
Decreased by -20.8%
Decreased by -89.32%
Jun 30, 22 134.56 M
Increased by +16.79%
-34.01 M
Increased by +22.47%
Decreased by -25.28%
Increased by +33.62%
Mar 31, 22 115.47 M
Increased by +8.37%
-113.06 M
Decreased by -70.14%
Decreased by -97.91%
Decreased by -57.01%
Dec 31, 21 130.76 M
Increased by +8.06%
-43.09 M
Increased by +35.45%
Decreased by -32.96%
Increased by +40.26%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.